GlassScriptPhysician profile
Malini Rusia
NPI 1588827489
$1,947.87
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,560 · 2020: $388.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $239.04 | 2019-2020 | |
| Lilly USA, LLC | $199.38 | 2019-2020 | |
| Ucb, INC. | $197.40 | 2019 | |
| Glaxosmithkline, LLC. | $174.25 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $167.56 | 2019 | |
| Abbvie INC. | $156.34 | 2019-2020 | |
| Genzyme Corporation | $138.79 | 2019-2020 | |
| Amgen INC. | $136.70 | 2019-2020 | |
| Celgene Corporation | $117.48 | 2019 | |
| Pacira Therapeutics, INC. | $111.66 | 2019 | |
| Horizon Therapeutics Plc | $71.60 | 2019-2020 | |
| Genentech USA, INC. | $66.84 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $60.14 | 2020 | |
| Medexus Pharma, INC. | $56.09 | 2019-2020 | |
| Tersera Therapeutics LLC | $30.48 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.12 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malini Rusia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.